hsk44459
Idiopathic Pulmonary Fibrosis
Haisco Pharmaceutical Group Co., Ltd.Phase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
107 Active assets in the Idiopathic Pulmonary Fibrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pirfenidone Endeavor Biomedicines, Inc. | Phase 4 | A |
N-Acetyl-L-Cysteine Endeavor Biomedicines, Inc. | Phase 4 | BBB |
Nintedanib Mannkind Corporation | Phase 4 | BBB |
Nerandomilast Boehringer Ingelheim | Phase 3 | BB |
PREDNISONE TABLETS Fondation Hôpital Saint-Joseph | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →